NEW YORK (GenomeWeb News) – Agilent Technologies said today that French biotech firm Imaxio has achieved Certified Service Provider status for the SureSelect Target Enrichment System for next-generation sequencing.

Imaxio was already a CSP for Agilent's microarray services and participated in comprehensive on-site training and passed a set of requirements demonstrating expertise and skill to receive CSP status for the SureSelect system, Agilent said. SureSelect is compatible with major NGS platforms, such as Illumina, Life Technologies' SOLiD, and Roche's 454.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.